Simultaneous assessment of P53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia

Polish Journal of Pathology

Volumn 61, Issue 4, 2010, Pages 199-205

  Ociepa, Tomasz ^a   Maloney, Eliza ^a   Kamieńska, Elzbieta ^a   Wysocki, Mariusz ^b   Kurylak, Andrzej ^b   Matysiak, Michal ^c   Urasiński, Tomasz ^a   Urasińska, Elzbieta ^a   Domagala, Wenancjusz ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Acute lymphoblastic leukemia; Children; Early treatment response; MDM2; p53

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; MDM2 PROTEIN, HUMAN; PREDNISONE; PROTEIN MDM2; PROTEIN P53; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; DRUG EFFECT; FEMALE; HUMAN; INFANT; MALE; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; PRESCHOOL CHILD; TIME;

ADOLESCENT; ANTINEOPLASTIC AGENTS, HORMONAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKOCYTES, MONONUCLEAR; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; PROTO-ONCOGENE PROTEINS C-MDM2; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79953323998     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Dördelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209-1217.
2. Schrappe M. Evolution of BFM trials for childhood ALL. Ann Hematol 2004; 83 Suppl 1: S121-123.
3. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211-1218.
4. Klimza MJ, Sonta-Jakimczyk DJ. Prognostic value of the initial response to corticosteroids for children with acute lymphoblastic leukemia. Wiad Lek 2005; 58: 622-625.
5. Greenstein S, Ghias K, Krett NL, Rosen ST. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 2002; 8: 1681-1694.
6. Liu T, Raetz E, Moos PJ, et al. Diversity of the apoptotic response to chemotherapy in childhood leukemia. Leukemia 2002; 16: 223-232.
7. Renner K, Ausserlechner MJ, Kofler R. A conceptual view on glucocorticoid-induced apoptosis, cell cycle arrest and glucocorticoid resistance in lymphoblastic leukemia. Curr Mol Med 2003; 3: 707-717.
8. Funakoshi Y, Shiono H, Inoue M, et al. Glucocorticoids induce G1 cell cycle arrest in human neoplastic thymic epithelial cells. J Cancer Res Clin Oncol 2005; 131: 314-322.
9. Rogatsky I, Trowbridge JM, Garabedian MJ. Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms. Mol Cell Biol 1997; 17: 3181-3193.
10. Insinga A, Monestiroli S, Ronzoni S, et al. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J 2004; 23: 1144-1154.
11. Kim R. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 2005; 103: 1551-1560.
12. Liang SH, Clarke MF. Regulation of p53 localization. Eur J Biochem 2001; 268: 2779-2783.
13. Schimmer AD, Hedley DW, Penn LZ, Minden MD. Receptor-and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood 2001; 98: 3541-3553.
14. Shimizu S, Shinohara Y, Tsujimoto Y. Bax and Bcl-xL independently regulate apoptotic changes of yeast mitochondria that require VDAC but not adenine nucleotide translocator. Oncogene 2000; 19: 4309-4318.
15. Boyd SD, Tsai KY, Jacks T. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol 2000; 2: 563-568.
16. Coutts AS, La Thangue NB. Mdm2 widens its repertoire. Cell Cycle 2007; 6: 827-829.
17. Geyer RK, Yu ZK, Maki CG. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol 2000; 2: 569-573.
18. Zhu H, Wu L, Maki CG. MDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53. J Biol Chem 2003; 278: 49286-49292.
19. Capoulade C, Mir LM, Carlier K, et al. Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides. Blood 2001; 97: 1043-1049.
20. Coll-Mulet L, Iglesias-Serret D, Santidrián AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006; 107: 4109-4114.
21. O'Keefe K, Li H, Zhang Y. Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. Mol Cell Biol 2003; 23: 6396-6405.
22. Ganguli G, Wasylyk B. p53-independent functions of MDM2. Mol Cancer Res 2003; 14: 1027-1035.
23. Gustafsson B, Axelsson B, Gustafsson B, et al. MDM2 and p53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to longterm survivors. Pediatr Hematol Oncol 2001; 18: 497-508.
24. Zhu N, Gu L, Li F, Zhou M. Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Mol Cancer Ther 2008; 7: 1101-1109.
25. Gu L, Zhu N, Findley HW, Zhou M. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia 2008; 22: 730-739.
26. Smolewski P, Grabarek J, Lee BW, et al. Kinetics of HL-60 cell entry to apoptosis during treatment with TNF-alpha or camptothecin assayed by the stathmo-apoptosis method. Cytometry 2002; 47: 143-149.
27. Urasinski T, Urasinska E, Grabarek J, et al. Good early treatment response in childhood acute lymphoblastic leukemia is associated with Bax nuclear accumulation and PARP cleavage. Med Sci Monit 2009; 15: CR294-301.
28. Groninger E, de Graaf SS, Meeuwsen-de Boer GJ, et al. Vincristine-induced apoptosis in vivo in peripheral blood mononuclear cells of children with acute lymphoblastic leukaemia (ALL). Br J Haematol 2000; 111: 875-878.
29. Pan Y, Haines DS. The pathway regulating MDM2 protein degradation can be altered in human leukemic cells. Cancer Res 1999; 59: 2064-2067.
30. Wojcik I, Szybka M, Golanska E, et al. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias. J Neoplasma 2005; 52: 318-324.
31. Zhou M, Gu L, Abshire TC, et al. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 61-67.
32. Zhou M, Gu L, Findley HW, Jiang R, Woods WG. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res 2003; 63: 6357-6362.
33. Gustafsson B, Christenson B, Hjalmar V, Winiarski J. Cellular expression of MDM2 and p53 in childhood leukemias with poor prognosis. Med Pediatr Oncol 2000; 34: 117-124.
34. Lam V, McPherson JP, Salmena L, et al. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leuk Res 1999; 23: 871-880.
35. Peller S, Rotter V. TP53 in Hematological Cancer: Low Incidence of Mutations With Significant Clinical Relevance. Human Mutation 2003; 21: 277-284.
36. Nouman GS, Anderson JJ, Wood KM, et al. Loss of nuclear expression of the p33(ING1b) inhibitor of growth protein in childhood acute lymphoblastic leukaemia. J Clin Pathol 2002; 55: 596-601.
37. Cao C, Shinohara ET, Subhawong TK, et al. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Mol Cancer Ther 2006; 5: 411-417.
38. Kojima K, Konopleva M, McQueen T, et al. Mdm2 inhibitor Nutlin-3a induces p53-mediated 15apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006; 108: 993-1000.
39. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106: 3150-3159.
40. Secchiero P, Barbarotto E, Tiribelli M, et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006; 107: 4122-4129.
41. Hendy OM, Elghannam DM, El-Sharnouby JA, et al. Frequency and prognostic significance of murine double minute protein-2 overexpression and p53 gene mutations in childhood acute lymphoblastic leukemia. Hematology 2009; 14: 335-340.